|Bid||8.6700 x 300|
|Ask||8.6900 x 100|
|Day's range||8.2750 - 9.1400|
|52-week range||5.9000 - 25.1700|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2017 - 3 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||23.17|
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation into potential breaches of fiduciary duty by the Company’s Board of Directors .
AMES, Iowa, Dec. 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 11:00am PT / 2:00pm ET in San Francisco, CA.
The Ames, Iowa-based company said it had a loss of 69 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
NewLink Genetics Corporation , a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares of its common stock in an underwritten public offering.
ASCO's abstract drop reveals the progress being made in attacking cancer and, inevitably, moves stocks both large and small.